Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | AXL | P30530 | 3/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4506549 | 0.82 | KDM4E (0.50) | HPGDSLC6A4SLC6A3FFAR4MEN1 | |
| SCHEMBL12392026 | 0.80 | F2 (0.40) | SCN8ASCN10APNLIP | |
| SCHEMBL27850308 | 0.78 | SLC6A3 (0.64) | HPGDSLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL15912486 | 0.78 | FFAR4 (0.49) | HPGDSLC6A4SLC6A3FFAR4MEN1 | |
| SCHEMBL1741581 | 0.77 | SLC6A3 (0.51) | HPGDSLC6A4SLC6A3FFAR4MEN1 | |
| SCHEMBL21274571 | 0.74 | HPGD (0.52) | HPGDSLC6A4SLC6A3KMT2AALDH1A1 | |
| SCHEMBL8272377 | 0.72 | FPR2 (0.47) | HPGDSLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL27919697 | 0.72 | KMT2A (0.50) | HPGDSLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL21359388 | 0.72 | HSD17B10 (0.48) | HPGDSLC6A4SLC6A3KMT2AALDH1A1 | |
| SCHEMBL4449413 | 0.72 | PTGER4 (0.57) | HPGDSLC6A4SLC6A3ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404893-B2 | Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-03-26 | — | — | US | disclosed |
| US-20110306670-A1 | PENTAFLUOROSULFANYLBENZOYLGUANIDINES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS OR DIAGNOSTIC AIDS, AND MEDICAMENTS COMPRISING THEM | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-12-15 | — | — | US | disclosed |
| US-8008352-B2 | N-[2-Chloro-4-pentafluorosulfanylbenzoyl]guanidine; ischemia, reperfusion, arrythmia angina pectoris; inhibit the cellular sodium-proton antiporter (Na+/H+ exchanger, NHE); stability, longer half-life in vivo, high bioavailability | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-08-30 | — | — | US | disclosed |
| US-20080200553-A1 | PENTAFLUOROSULFANYLBENZOYLGUANIDINES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS OR DIAGNOSTIC AIDS, AND MEDICAMENTS COMPRISING THEM | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-08-21 | — | — | US | disclosed |
| US-7375138-B2 | Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-05-20 | — | — | US | disclosed |
| US-20030216476-A1 | Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them | AVENTIS PHARMA DEUTSHCHLAND GMBH (DE) | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200553-A1 | PENTAFLUOROSULFANYLBENZOYLGUANIDINES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS OR DIAGNOSTIC AIDS, AND MEDICAMENTS COMPRISING THEM | TNNI3, TNNT2, SDHB | HPGD 2102/4885SLC6A4 2822/4885SLC6A3 4150/4885 |
| US-20110306670-A1 | PENTAFLUOROSULFANYLBENZOYLGUANIDINES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS OR DIAGNOSTIC AIDS, AND MEDICAMENTS COMPRISING THEM | TNNI3, TNNT2, SDHB | HPGD 2102/4885SLC6A4 2822/4885SLC6A3 4150/4885 |
| US-20030216476-A1 | Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them | TNNI3, TNNT2, SDHB | HPGD 2080/4885SLC6A4 2973/4885SLC6A3 4276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.